- Home
- RGNX vs CDXS Comparison
RGNX vs CDXS Comparison
Compare RGNX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- CDXS
- Stock Information
- Founded
- RGNX 2008
- CDXS 2002
- Country
- RGNX United States
- CDXS United States
- Employees
- RGNX N/A
- CDXS N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- CDXS Major Chemicals
- Sector
- RGNX Health Care
- CDXS Industrials
- Exchange
- RGNX Nasdaq
- CDXS Nasdaq
- Market Cap
- RGNX 372.1M
- CDXS 406.9M
- IPO Year
- RGNX 2015
- CDXS 2010
- Fundamental
- Price
- RGNX $7.57
- CDXS $5.13
- Analyst Decision
- RGNX Strong Buy
- CDXS Buy
- Analyst Count
- RGNX 12
- CDXS 2
- Target Price
- RGNX $35.55
- CDXS $11.00
- AVG Volume (30 Days)
- RGNX 1.8M
- CDXS 739.7K
- Earning Date
- RGNX 02-25-2025
- CDXS 02-26-2025
- Dividend Yield
- RGNX N/A
- CDXS N/A
- EPS Growth
- RGNX N/A
- CDXS N/A
- EPS
- RGNX N/A
- CDXS N/A
- Revenue
- RGNX $84,327,000.00
- CDXS $64,446,000.00
- Revenue This Year
- RGNX $2.92
- CDXS N/A
- Revenue Next Year
- RGNX $256.82
- CDXS $2.02
- P/E Ratio
- RGNX N/A
- CDXS N/A
- Revenue Growth
- RGNX N/A
- CDXS N/A
- 52 Week Low
- RGNX $6.56
- CDXS $2.53
- 52 Week High
- RGNX $28.80
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- RGNX 45.51
- CDXS 58.39
- Support Level
- RGNX $6.98
- CDXS $4.24
- Resistance Level
- RGNX $7.70
- CDXS $5.51
- Average True Range (ATR)
- RGNX 0.54
- CDXS 0.32
- MACD
- RGNX 0.04
- CDXS 0.00
- Stochastic Oscillator
- RGNX 44.30
- CDXS 82.68
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.